Offerings (SEC Form D)
Each filing as reported by the issuer, newest first. Open a row for the full plain-English detail. D = original notice, D/A = amendment.
Offerings at a glance — 6 offerings, 9 filings (one row per SEC file number)
| File no. | Original Form D | Latest filing | Amendments | Offered (latest) | Sold (latest) | Industry (latest) |
|---|
| 021-382789 | Dec 10, 2020 EDGAR ↗ | Dec 10, 2020 D EDGAR ↗ | 0 | $23,249,972 | $23,249,972 | Biotechnology |
| 021-364881 | Apr 14, 2020 EDGAR ↗ | Apr 14, 2020 D/A EDGAR ↗ | 1 latest Apr 14, 2020 | $30,500,000 | $30,150,002 | Biotechnology |
| 021-347396 | Aug 26, 2019 EDGAR ↗ | Sep 10, 2019 D/A EDGAR ↗ | 1 latest Sep 10, 2019 | $31,502,481 | $30,749,980 | Biotechnology |
| 021-291189 | Jul 20, 2017 EDGAR ↗ | Jun 4, 2018 D/A EDGAR ↗ | 1 latest Jun 4, 2018 | $22,226,216 | $19,726,217 | Biotechnology |
| 021-250429 | Oct 30, 2015 EDGAR ↗ | Oct 30, 2015 D EDGAR ↗ | 0 | $7,000,000 | $6,939,969 | Biotechnology |
| 021-166465 | Sep 28, 2011 EDGAR ↗ | Sep 28, 2011 D EDGAR ↗ | 0 | $5,249,995 | $524,995 | Biotechnology |
Offerings are grouped by SEC file number; rows without a file number (not yet retrieved from EDGAR) are shown as their own offering until the link is fetched.
Dec 10, 2020 D Biotechnology — $23,249,972 sold of $23,249,972 · 4 investors EDGAR ↗
| Filing | Form D filed Dec 10, 2020SEC file no. 021-382789 · accession 0001567619-20-020828 |
|---|
| Raise progress | $23,249,972 sold of $23,249,972 offered (100%) · $0 remaining · first sale Nov 23, 2020 |
|---|
| Filing timing | Date of first sale: Nov 23, 2020 · Form D filed: Dec 10, 2020 (17 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 2,161 days (5.9 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 4 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
|---|
| Minimum investment accepted | $0 as filed (no minimum reported) |
|---|
| Securities offered | Equity |
|---|
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Biotechnology |
|---|
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
|---|
| Signed by | Jesse Selnick, Chief Financial Officer (Dec 9, 2020) |
|---|
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000.
Offering size: $23,249,972. Typical range: $2,000,000–$19,999,994.
Investors: 4. Typical range: 2–16."Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Apr 14, 2020 D/A Biotechnology — $30,150,002 sold of $30,500,000 · 4 investors EDGAR ↗
| Filing | Form D/A (amendment) filed Apr 14, 2020 · amends 0001567619-20-007904 ↗SEC file no. 021-364881 · accession 0001567619-20-007916 · filing 2 of 2 in this offering |
|---|
| Raise progress | $30,150,002 sold of $30,500,000 offered (99%) · $349,998 remaining · first sale Mar 17, 2020 |
|---|
| Filing timing | Date of first sale: Mar 17, 2020 · Original Form D filed: Apr 14, 2020 (28 days after first sale) · This amendment (Form D/A) filed: Apr 14, 2020 This row is an amendment. Rule: the original Form D is generally due within 15 days after the first sale; the rule sets no deadline measured from an amendment. Dates shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 2,412 days (6.6 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. This filing is an amendment dated Apr 14, 2020. Most recent amendment for this offering in our index: this filing, Apr 14, 2020. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 4 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
|---|
| Minimum investment accepted | $0 as filed (no minimum reported) |
|---|
| Securities offered | Equity |
|---|
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Biotechnology |
|---|
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
|---|
| Signed by | Jesse Selnick, Chief Financial Officer (Apr 14, 2020) |
|---|
| Changes vs previous filing | - investors: 0 (Apr 14, 2020) → 4 (Apr 14, 2020)
Compared with the D filed Apr 14, 2020 ( EDGAR ↗). Fields compared: total sold, total offering, remaining, investors, non-accredited investors (count), non-accredited investors reported, minimum investment, sales commissions, finder's fees, proceeds to insiders, date of first sale, industry, fund type, exemption, revenue range, net asset value range, securities offered, may last more than one year, related persons, sales-compensation recipients. Amendment history as filed; no conclusion is drawn. |
|---|
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000.
Offering size: $30,500,000. Typical range: $2,000,000–$19,999,994.
Investors: 4. Typical range: 2–16."Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Apr 14, 2020 D Biotechnology — $30,150,002 sold of $30,500,000 · 0 investors EDGAR ↗
| Filing | Form D filed Apr 14, 2020SEC file no. 021-364881 · accession 0001567619-20-007904 · filing 1 of 2 in this offering |
|---|
| Raise progress | $30,150,002 sold of $30,500,000 offered (99%) · $349,998 remaining · first sale Mar 17, 2020 |
|---|
| Filing timing | Date of first sale: Mar 17, 2020 · Form D filed: Apr 14, 2020 (28 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 2,412 days (6.6 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Most recent amendment for this offering in our index: Apr 14, 2020 (EDGAR ↗). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 0 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
|---|
| Minimum investment accepted | $0 as filed (no minimum reported) |
|---|
| Securities offered | Equity |
|---|
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Biotechnology |
|---|
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
|---|
| Signed by | Jesse Selnick, Chief Financial Officer (Apr 13, 2020) |
|---|
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000.
Offering size: $30,500,000. Typical range: $2,000,000–$19,999,994.
Investors: 0. Typical range: 2–16."Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Sep 10, 2019 D/A Biotechnology — $30,749,980 sold of $31,502,481 · 2 investors EDGAR ↗
| Filing | Form D/A (amendment) filed Sep 10, 2019 · amends 0001531177-19-000001 ↗SEC file no. 021-347396 · accession 0001531177-19-000002 · filing 2 of 2 in this offering |
|---|
| Raise progress | $30,749,980 sold of $31,502,481 offered (98%) · $752,501 remaining · first sale Aug 9, 2019 |
|---|
| Filing timing | Date of first sale: Aug 9, 2019 · Original Form D filed: Aug 26, 2019 (17 days after first sale) · This amendment (Form D/A) filed: Sep 10, 2019 This row is an amendment. Rule: the original Form D is generally due within 15 days after the first sale; the rule sets no deadline measured from an amendment. Dates shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 2,633 days (7.2 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. This filing is an amendment dated Sep 10, 2019. Most recent amendment for this offering in our index: this filing, Sep 10, 2019. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 2 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
|---|
| Minimum investment accepted | $0 as filed (no minimum reported) |
|---|
| Securities offered | Equity |
|---|
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Biotechnology |
|---|
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $500,000 · Proceeds to officers, directors, promoters: $0 |
|---|
| Signed by | Jesse Selnick, Chief Financial Officer (Sep 10, 2019) |
|---|
| Changes vs previous filing | - finder's fees: $0 (Aug 26, 2019) → $500,000 (Sep 10, 2019)
Compared with the D filed Aug 26, 2019 ( EDGAR ↗). Fields compared: total sold, total offering, remaining, investors, non-accredited investors (count), non-accredited investors reported, minimum investment, sales commissions, finder's fees, proceeds to insiders, date of first sale, industry, fund type, exemption, revenue range, net asset value range, securities offered, may last more than one year, related persons, sales-compensation recipients. Amendment history as filed; no conclusion is drawn. |
|---|
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000.
Offering size: $31,502,481. Typical range: $2,000,000–$19,999,994.
Investors: 2. Typical range: 2–16."Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Aug 26, 2019 D Biotechnology — $30,749,980 sold of $31,502,481 · 2 investors EDGAR ↗
| Filing | Form D filed Aug 26, 2019SEC file no. 021-347396 · accession 0001531177-19-000001 · filing 1 of 2 in this offering |
|---|
| Raise progress | $30,749,980 sold of $31,502,481 offered (98%) · $752,501 remaining · first sale Aug 9, 2019 |
|---|
| Filing timing | Date of first sale: Aug 9, 2019 · Form D filed: Aug 26, 2019 (17 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 2,633 days (7.2 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Most recent amendment for this offering in our index: Sep 10, 2019 (EDGAR ↗). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 2 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
|---|
| Minimum investment accepted | $0 as filed (no minimum reported) |
|---|
| Securities offered | Equity |
|---|
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Biotechnology |
|---|
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
|---|
| Signed by | Jesse Selnick, Chief Financial Officer (Aug 26, 2019) |
|---|
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000.
Offering size: $31,502,481. Typical range: $2,000,000–$19,999,994.
Investors: 2. Typical range: 2–16."Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Jun 4, 2018 D/A Biotechnology — $19,726,217 sold of $22,226,216 · 25 investors EDGAR ↗
| Filing | Form D/A (amendment) filed Jun 4, 2018 · amends 0001531177-17-000001 ↗SEC file no. 021-291189 · accession 0001531177-18-000001 · filing 2 of 2 in this offering |
|---|
| Raise progress | $19,726,217 sold of $22,226,216 offered (89%) · $2,499,999 remaining · first sale Jul 7, 2017 |
|---|
| Filing timing | Date of first sale: Jul 7, 2017 · Original Form D filed: Jul 20, 2017 (13 days after first sale) · This amendment (Form D/A) filed: Jun 4, 2018 This row is an amendment. Rule: the original Form D is generally due within 15 days after the first sale; the rule sets no deadline measured from an amendment. Dates shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 3,396 days (9.3 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. This filing is an amendment dated Jun 4, 2018. Most recent amendment for this offering in our index: this filing, Jun 4, 2018. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 25 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
|---|
| Minimum investment accepted | $0 as filed (no minimum reported) |
|---|
| Securities offered | Equity |
|---|
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Biotechnology |
|---|
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
|---|
| Signed by | Stephen Thau, Secretary (May 31, 2018) |
|---|
| Changes vs previous filing | - total sold: $10,000,000 (Jul 20, 2017) → $19,726,217 (Jun 4, 2018)
- total offering: $10,000,000 (Jul 20, 2017) → $22,226,216 (Jun 4, 2018)
- remaining: $0 (Jul 20, 2017) → $2,499,999 (Jun 4, 2018)
- investors: 15 (Jul 20, 2017) → 25 (Jun 4, 2018)
- related persons added (Jun 4, 2018): Jesse Selnick
Compared with the D filed Jul 20, 2017 ( EDGAR ↗). Fields compared: total sold, total offering, remaining, investors, non-accredited investors (count), non-accredited investors reported, minimum investment, sales commissions, finder's fees, proceeds to insiders, date of first sale, industry, fund type, exemption, revenue range, net asset value range, securities offered, may last more than one year, related persons, sales-compensation recipients. Amendment history as filed; no conclusion is drawn. |
|---|
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000.
Offering size: $22,226,216. Typical range: $2,000,000–$19,999,994.
Investors: 25. Typical range: 2–16."Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Jul 20, 2017 D Biotechnology — $10,000,000 sold of $10,000,000 · 15 investors EDGAR ↗
| Filing | Form D filed Jul 20, 2017SEC file no. 021-291189 · accession 0001531177-17-000001 · filing 1 of 2 in this offering |
|---|
| Raise progress | $10,000,000 sold of $10,000,000 offered (100%) · $0 remaining · first sale Jul 7, 2017 |
|---|
| Filing timing | Date of first sale: Jul 7, 2017 · Form D filed: Jul 20, 2017 (13 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 3,396 days (9.3 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Most recent amendment for this offering in our index: Jun 4, 2018 (EDGAR ↗). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 15 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
|---|
| Minimum investment accepted | $0 as filed (no minimum reported) |
|---|
| Securities offered | Equity |
|---|
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Biotechnology |
|---|
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
|---|
| Signed by | Stephen Thau, Secretary (Jul 20, 2017) |
|---|
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000.
Offering size: $10,000,000. Typical range: $2,000,000–$19,999,994.
Investors: 15. Typical range: 2–16."Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Oct 30, 2015 D Biotechnology — $6,939,969 sold of $7,000,000 · 17 investors EDGAR ↗
| Filing | Form D filed Oct 30, 2015SEC file no. 021-250429 · accession 0001531177-15-000002 |
|---|
| Raise progress | $6,939,969 sold of $7,000,000 offered (99%) · $60,031 remaining · first sale Oct 16, 2015 |
|---|
| Filing timing | Date of first sale: Oct 16, 2015 · Form D filed: Oct 30, 2015 (14 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 4,026 days (11.0 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 17 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
|---|
| Minimum investment accepted | $0 as filed (no minimum reported) |
|---|
| Securities offered | Equity |
|---|
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Biotechnology |
|---|
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
|---|
| Signed by | Stephen Thau, Secretary (Oct 29, 2015) |
|---|
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000.
Offering size: $7,000,000. Typical range: $2,000,000–$19,999,994.
Investors: 17. Typical range: 2–16."Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Sep 28, 2011 D Biotechnology — $524,995 sold of $5,249,995 · 6 investors EDGAR ↗
| Filing | Form D filed Sep 28, 2011SEC file no. 021-166465 · accession 0001531177-11-000001 |
|---|
| Raise progress | $524,995 sold of $5,249,995 offered (10%) · $4,725,000 remaining · first sale Sep 12, 2011 |
|---|
| Filing timing | Date of first sale: Sep 12, 2011 · Form D filed: Sep 28, 2011 (16 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 5,521 days (15.1 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 6 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c)) |
|---|
| Minimum investment accepted | $0 as filed (no minimum reported) |
|---|
| Securities offered | Equity |
|---|
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Biotechnology |
|---|
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
|---|
| Signed by | Paul Badawi, President (Sep 27, 2011) |
|---|
| Market context | Not computed — the exemption as filed is Rule 506 before the Sept 2013 split into 506(b) and 506(c) (see Exemption claimed); ranges are computed only for offerings claiming Rule 506(b) or 506(c), compared with the last 5 years of filings. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Amendment history — 3 amendments on this page, each compared with the filing before it in the same offering
| Amendment filed | File no. | Compared with | What changed (both values as filed) |
|---|
| Apr 14, 2020 EDGAR ↗ | 021-364881 | Apr 14, 2020 D | investors: 0 (Apr 14, 2020) → 4 (Apr 14, 2020) |
| Sep 10, 2019 EDGAR ↗ | 021-347396 | Aug 26, 2019 D | finder's fees: $0 (Aug 26, 2019) → $500,000 (Sep 10, 2019) |
| Jun 4, 2018 EDGAR ↗ | 021-291189 | Jul 20, 2017 D | total sold: $10,000,000 (Jul 20, 2017) → $19,726,217 (Jun 4, 2018) · total offering: $10,000,000 (Jul 20, 2017) → $22,226,216 (Jun 4, 2018) · remaining: $0 (Jul 20, 2017) → $2,499,999 (Jun 4, 2018) · and 2 more (open the filing above) |
Fields compared: total sold, total offering, remaining, investors, non-accredited investors (count), non-accredited investors reported, minimum investment, sales commissions, finder's fees, proceeds to insiders, date of first sale, industry, fund type, exemption, revenue range, net asset value range, securities offered, may last more than one year, related persons, sales-compensation recipients. Values as filed; no conclusion is drawn.
All Form D filings for this CIK on SEC EDGAR ↗. History: 0 new offerings in the last 12 months (new offering = a Form D that is not an amendment) · most recent filing Dec 10, 2020. Industry as reported, by offering: All 6 offerings reported: Biotechnology (2011–2020).
Key people 12
Officers, directors and promoters the issuer itself named on its Form D. Tap a name for every other deal they are on.
| Name | Relationship | Address state | On filings (first → last) | Also listed on |
|---|
| AO Andrew Offer | Director | CA | Dec 10, 2020 on 1 of 9 filings listed on the latest filing | 3 other issuers |
| DB David Badawi | Director | CA | Sep 28, 2011 → Dec 10, 2020 on 9 of 9 filings listed on the latest filing | — |
| DZ Don Zurbay | Director | CA | Dec 10, 2020 on 1 of 9 filings listed on the latest filing | — |
| ER Erica Rogers | Director | CA | Apr 14, 2020 → Dec 10, 2020 on 3 of 9 filings listed on the latest filing | 1 other issuer |
| JS Jesse Selnick | Executive Officer | CA | Jun 4, 2018 → Dec 10, 2020 on 6 of 9 filings listed on the latest filing | — |
| MH Mack Hicks | Director | TX | Sep 28, 2011 → Dec 10, 2020 on 9 of 9 filings listed on the latest filing | 10 other issuers |
| PB Paul Badawi | Executive Officer, Director | CA | Sep 28, 2011 → Dec 10, 2020 on 9 of 9 filings listed on the latest filing | 1 other issuer |
| SE Staffan Encrantz | Director | CA | Jul 20, 2017 → Dec 10, 2020 on 7 of 9 filings listed on the latest filing | 2 other issuers |
| VS Valeska Schroeder | Director | CA | Aug 26, 2019 → Dec 10, 2020 on 5 of 9 filings listed on the latest filing | 2 other issuers |
| CM Carter Meyer | Director | TX | Sep 28, 2011 → Apr 14, 2020 on 8 of 9 filings not listed on the latest filing (Dec 10, 2020) | 14 other issuers |
| ST Stephen Thau | Executive Officer | CA | Aug 26, 2019 → Sep 10, 2019 on 2 of 9 filings not listed on the latest filing (Dec 10, 2020) | 3 other issuers |
| TH Tommy Hicks | Director | CA | Oct 30, 2015 on 1 of 9 filings not listed on the latest filing (Dec 10, 2020) | — |
Executive officers, directors and promoters as self-reported by the issuer, one row per person. Spellings of the same name (same first and last name, or the same full name that EDGAR split differently into middle and last name) with no conflicting middle initial are shown on one row (none on this issuer); dates and counts come from the filings that list each name. Licensed persons: FINRA BrokerCheck ↗ · SEC IAPD ↗.
Connections
Other issuers listing the same people:
- HH-GPS LP — Mack Hardin Hicks · latest filing Oct 16, 2026
- MiNDERA Corp — Andrew Offer · latest filing Jul 28, 2026
- Beneficient — Mack Hardin Hicks · latest filing Jul 24, 2026
- BRIUS Technologies, Inc. — Carter Meyer · latest filing Jul 23, 2026
- Potrero Medical, Inc. — Carter Meyer · latest filing May 29, 2026
- Potrero Medical, Inc. — Andrew Offer · latest filing May 29, 2026
- Spirair, Inc. — Carter Meyer · latest filing Mar 10, 2026
- HH-KSM LP — Mack Hardin Hicks · latest filing Jan 6, 2026
- HH-Tvshka KSM, LP — Mack Hardin Hicks · latest filing Jan 6, 2026
- Lhotse Medical, Inc. — Carter Meyer · latest filing May 6, 2025
- Aerin Medical Inc. — Valeska Schroeder · latest filing Dec 30, 2024
- Rivermark Medical, Inc. — Carter Meyer · latest filing Oct 11, 2024
- Empirical Spine, Inc. — Andrew Offer · latest filing Jun 20, 2024
- Channel Medsystems, Inc. — Carter Meyer · latest filing Mar 29, 2024
- Artelon, Inc. — Carter Meyer · latest filing Jun 2, 2023
- HICKS STRUCTURED EQUITY FUND I, L.P. — Mack Hardin Hicks · latest filing Dec 17, 2021
- HSEF I BU CO-INVEST, L.P. — Mack Hardin Hicks · latest filing Dec 17, 2021
- CLOSINGCORP INC — Staffan Encrantz · latest filing Jan 8, 2020
- BioEclipse Therapeutics, Inc. — Stephen Thau · latest filing Oct 10, 2019
- Intuity Medical, Inc. — Valeska Schroeder · latest filing May 29, 2019
- Complexa Inc. — Carter Meyer · latest filing Apr 16, 2019
- Replacement Parts Holdings LLC — Mack Hardin Hicks · latest filing Mar 15, 2019
- HH-Halo LP — Mack Hardin Hicks · latest filing Nov 29, 2018
- Esculon, Inc. — Carter Meyer · latest filing Nov 27, 2017
- Sotera Wireless, Inc. — Paul Badawi · latest filing Jul 26, 2017
- Silk Road Medical Inc — Erica Rogers · latest filing Jul 19, 2017
- HH-Utility LP — Mack Hardin Hicks · latest filing May 31, 2017
- GovX, Inc. — Staffan Encrantz · latest filing Oct 26, 2016
- DNANEXUS, INC. — Stephen Thau · latest filing Apr 23, 2015
- EMKINETICS INC — Carter Meyer · latest filing Feb 20, 2014
- AZEVAN PHARMACEUTICALS INC — Carter Meyer · latest filing Oct 18, 2013
- ANTERIOS INC — Carter Meyer · latest filing Apr 9, 2013
- Hicks Acquisition CO II, Inc. — Mack Hardin Hicks · latest filing Jun 28, 2010
- BAXANO, INC. — Stephen Thau · latest filing Jun 18, 2010
- SCIENTIFIC HEALTH DEVELOPMENT II, LTD. — Carter Meyer · latest filing Mar 2, 2010
- CURE DM INC — Carter Meyer · latest filing Aug 10, 2009
Shared address: this business address appears on filings for 3 other issuers. Stated as a count only (suite numbers ignored) — many addresses are shared office buildings or registered agents. As of Oct 23, 2026, 5:45 PM ET.
Other offering types (Regulation A and Regulation Crowdfunding)
Searched SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 (51,358 records as of Oct 23, 2026, 8:41 PM ET) — nothing matched this name.
Adviser registration (Form ADV)
Searched SEC Form ADV bulk data (registered + exempt reporting advisers) (24,962 records as of Oct 2, 2026, 8:00 AM ET) — nothing matched Sight Sciences, Inc..
Meta advertising
No Meta Pixel ids or Facebook / Instagram page links on file for Sight Sciences, Inc. as of Oct 24, 2026 — the sponsor website is read for them once it is on file (runs automatically). Meta Ad Library: not searched by PartnerFacts (no API access); a one-tap Ad Library search is under Look further.
Public profiles
Public profiles official links and public statements, each with its source and date
No website or social profile named in Sight Sciences, Inc.'s SEC filings (Form C, Reg A, Form ADV; checked Oct 24, 2026). Web search for this name: #204,814 of 374,652 in line (14 issuers searched so far).
Sources searched for a website: Form C data set (issuer websites as filed), Form ADV data set (Item 1.I of matched advisers) — as of Oct 23, 2026, 11:20 PM ET: none on file for this issuer. The sponsor website, the Internet Archive and GDELT news index are read only once a site is on file; a sponsor's website comes from the issuer's own filings (Form C issuer website; EDGAR company profile), an approved profile claim, Form ADV Item 1.I of its matched adviser, or a web search for the issuer name confirmed on the site's own homepage. We never collect personal or family accounts.
Entity standing: not checked (no official programmatic source for CA yet).
Export this report as PDF (all source links + data timestamp) · Premium
Request diligence pack (Premium) PartnerFacts asks the sponsor for the standard information pack and delivers it to you labelled "provided by the sponsor".
Corrections log
No corrections have been requested for this page.
Filing-to-filing changes are in Amendment history above.